Rhenman & Partners Asset Management AB Has $10.27 Million Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Rhenman & Partners Asset Management AB lessened its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 18.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,600 shares of the company’s stock after selling 32,500 shares during the period. Rhenman & Partners Asset Management AB owned 0.24% of Structure Therapeutics worth $10,266,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. CWM LLC increased its holdings in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares during the period. State of Wyoming acquired a new position in shares of Structure Therapeutics in the second quarter worth approximately $28,000. Banque Cantonale Vaudoise acquired a new position in shares of Structure Therapeutics in the fourth quarter worth approximately $205,000. Finally, ProShare Advisors LLC bought a new stake in Structure Therapeutics in the fourth quarter valued at approximately $206,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $42.93 on Friday. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The stock’s 50-day moving average is $43.64 and its 200 day moving average is $57.18. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of -49.34 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. On average, sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on GPCR shares. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Canaccord Genuity Group started coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price on the stock. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Finally, BMO Capital Markets set a $145.00 target price on Structure Therapeutics and gave the company an “outperform” rating in a report on Tuesday, March 17th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.